What is it about?
Vismodegib is given orally to treat metastatic or advanced basal cell carcinoma. However, it can provoke serious side effects and this limits its use. It would be more rational to treat these conditions locally, i.e. by applying a topical formulation - a gel or cream to the site of the disease . This would target drug delivery to where it is needed and would also avoid exposing the rest of the body to the drug and thereby decrease the risk of side effects.
Featured Image
Why is it important?
This is the first report into the development of a topical formulation of vismodegib and indeed the first paper on the topical delivery of an inhibitor of the hedgehog pathway.
Perspectives
We hope that this proof-of-principle paper, which demonstrates that topical delivery is capable of delivering therapeutically relevant amounts of vismodegib to the skin, might pave the way for clinical studies and so help to improve upon existing therapies available to patients.
Prof Yogeshvar Kalia
Universite de Geneve
Read the Original
This page is a summary of: Polymeric micelle nanocarriers for targeted epidermal delivery of the hedgehog pathway inhibitor vismodegib: formulation development and cutaneous biodistribution in human skin, Expert Opinion on Drug Delivery, April 2019, Taylor & Francis,
DOI: 10.1080/17425247.2019.1609449.
You can read the full text:
Contributors
The following have contributed to this page
